James J. Collins

Insider Reports History

Entity
Individual
Location
C/O Fulcrum Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA
Signature
/s/ Mike Rhee, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by James J. Collins:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Senti Biosciences, Inc. Director Stock Option (Right to Buy) 62.5K Jul 10, 2024 Direct
Fulcrum Therapeutics, Inc. Director Stock Option (right to buy) 30K Jun 17, 2024 Direct
Orion Biotech Opportunities Corp. Director Class B ordinary shares 0 May 17, 2023 Direct

Insider Reports Filed by James J. Collins

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SNTI Senti Biosciences, Inc. Jul 10, 2024 1 $0 4 Jul 12, 2024 Director
FULC Fulcrum Therapeutics, Inc. Jun 17, 2024 1 $0 4 Jun 18, 2024 Director
FULC Fulcrum Therapeutics, Inc. Jun 27, 2023 1 $0 4 Jun 29, 2023 Director
SNTI Senti Biosciences, Inc. Jun 16, 2023 1 $0 4 Jun 21, 2023 Director
ORIA Orion Biotech Opportunities Corp. May 17, 2023 1 $0 4 May 18, 2023 Director
SNTI Senti Biosciences, Inc. Jul 13, 2022 1 $0 4 Jul 15, 2022 Director
FULC Fulcrum Therapeutics, Inc. Jun 27, 2022 1 $0 4 Jun 29, 2022 Director
SNTI Senti Biosciences, Inc.\ Jun 8, 2022 0 $0 3 Jun 15, 2022 Director
FULC Fulcrum Therapeutics, Inc. Jun 9, 2021 1 $0 4 Jun 11, 2021 Director
ORIA Orion Biotech Opportunities Corp. May 12, 2021 0 $0 3 May 12, 2021 Director